Trump’s latest 100 percent tariff on pharmaceuticals: What we know

Donald Trump announced a new 100% tariff on branded and patented pharmaceutical imports, effective October 1, with an exemption for companies establishing manufacturing in the U.S. This was accompanied by new tariffs on kitchen cabinets (50%), upholstered furniture (30%), and heavy trucks (25%). Following the announcement, pharmaceutical companies across Europe and Asia, including major Swiss, German, Japanese, and Indian firms, experienced share price declines. However, industry experts suggest the impact on some foreign producers, particularly Indian generic manufacturers, may be mitigated by existing U.S. operations, while PhRMA warned that such tariffs could deter investment in the U.S. pharmaceutical sector.

Analysis

The announcement of a 100% tariff on branded and patented pharmaceutical imports, effective October 1, introduces significant policy risk for the global pharma sector. The U.S. imported approximately $158 billion in pharmaceutical products in 2023, with key suppliers including Ireland, Switzerland, and Germany, which collectively accounted for over 41% of packaged medicament imports. The market's immediate reaction was negative, evidenced by share price declines across major European and Asian firms; Novartis (NVS) and Roche fell about 1.2%, Bayer dropped 1.5%, and Australia's CSL hit a six-year low. The Indian pharmaceuticals index also slid 2%, despite its focus on generics which are not explicitly targeted. However, the policy's impact may be mitigated by an exemption for companies that are actively building manufacturing plants in the U.S. and by the fact that many large foreign firms, particularly from India, already operate U.S.-based manufacturing or repackaging units. Experts like Mizuho's healthcare equity specialist suggest the impact could be "negligible" as major players have a domestic presence and have already announced increased local investment. Conversely, the industry group PhRMA warns that the tariffs could deter future U.S. investment by diverting capital that would otherwise be used for manufacturing and R&D.

Key Decisions for Investors

• Investors should immediately assess their portfolio's exposure to non-U.S. pharmaceutical companies, particularly those heavily reliant on exporting branded drugs to the U.S. with a minimal domestic manufacturing footprint.
• Consider re-evaluating positions in companies that demonstrated resilience, such as Takeda (TAK), which edged down only 0.1%, as their significant existing U.S. operations may insulate them from the direct impact of the tariffs.
• Monitor policy developments closely for specific implementation details, as the exemption for companies 'breaking ground' in the U.S. creates a binary risk profile and introduces significant execution uncertainty for firms planning to onshore manufacturing.
• Look for potential beneficiaries within the U.S. domestic pharmaceutical landscape, including contract development and manufacturing organizations (CDMOs) and drugmakers with primarily domestic production, who may gain a competitive advantage from the policy.